BioSpace News Archive

Valo Health LLC (Valo), the technology company working to transform the drug discovery and development process and accelerate the creation of life-changing drugs, closed a $190 million Series B financing and unveiled select therapeutic programs.

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of cardiovascular death and hospitalization for heart failure

Perrigo Company plc, a leading provider of Quality, Affordable Self-Care Products, announced a formal partnership with Michigan State University, connecting the university’s clinical and research expertise with Perrigo’s product innovation, manufacturing scale and retail partnerships to empower consumers to take control of their self-care needs.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001 , a topical formulation designed for the treatment of patients with rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment.

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, announced today a strategic collaboration with Almac Diagnostic Services, a global stratified medicine company, to enhance opportunities for clinical trial development and companion diagnostic (CDx) projects.

Eisai will present five abstracts across four tumor types at the Gastrointestinal Cancers Symposium (#GI21), which is being held virtually from January 15-17, 2021.

Resolution Bioscience, Inc. today announced a companion diagnostic agreement with Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company.

Establishment Labs Holdings Inc., a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, reported preliminary revenue and cash figures for the fourth quarter and fiscal year ended December 31, 2020.

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors has formed a strategic review committee with a view to enhancing shareholder value

Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PVSRIPO for the treatment of advanced melanoma (stage IIB-IV)